FLI1 and Ewing sarcoma: Specific and well-characterized genetic mutations, such as stromal antigen 2 (STAG2) and TP53 loss-of-function mutations, translocation events, and fusion genes [Most commonly, EWSR1-FLI1 and EWSR1-erythroblast transformation specific-related gene (ERG)], have been found expressed in Ewing sarcoma patients, leading to the opportunity to monitor this bone malignancy through ctDNA[102].